PRME
Prime Medicine, Inc.
PRME
Prime Medicine, Inc.
Shares of INLIF Ltd (NASDAQ:INLF) rose sharply in pre-market trading after the company reported a 26.01% net revenue rise in its unaudited first-half fiscal 2026 results.
With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-in-class gene-editing pipeline. PRME's therapies target five indications across liver, lung, and immu
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers p